PL9655 / Palatin Technologies - LARVOL DELTA

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 (PRNewswire) - "Key Findings: Vision preservation: PL9654 and PL9655 maintained contrast vision and showed significant efficacy compared to vehicle; Inflammation control: Gene set enrichment analysis revealed downregulation of immune-related pathways in microglia and Müller glial cells for PL9654 and PL9655 compared to vehicle; Retinal protection: PL9654 reduced ischemia-reperfusion-induced retinal damage (as measured by histological scoring), similar to the melanocortin peptide α-MSH; Anti-angiogenesis: PL9654 significantly inhibited choroidal neovascularization and fibrosis (P<0.01). PL9655 topical treatment also showed an increase in rods compared with vehicle."

Preclinical • Diabetic Retinopathy